The establishment of a reliable prenatal source of autologous, transgene-free progenitor cells has enormous potential in the development of regenerative-medicine-based therapies for infants born with devastating birth defects. Here, we show that a largely CD117-negative population of human amniotic fluid mesenchymal stromal cells (AF-MSCs) obtained from fetuses with or without prenatally diagnosed anomalies are readily abundant and have limited baseline differentiation potential when compared with bone-marrow-derived MSCs and other somatic cell types. Nonetheless, the AF-MSCs could be easily reprogrammed into induced pluripotent stem cells (iPSCs) using nonintegrating Sendai viral vectors encoding for OCT4, SOX2, KLF4, and cMYC. The iPSCs were virtually indistinguishable from human embryonic stem cells in multiple assays and could be used to generate a relatively homogeneous population of neural progenitors, expressing PAX6, SOX2, SOX3, Musashi-1, and PSA-NCAM, for potential use in neurologic diseases. Further, these neural progenitors showed engraftment potential in vivo and were capable of differentiating into mature neurons and astrocytes in vitro. This study demonstrates the usefulness of AF-MSCs as an excellent source for the generation of human transgene-free iPSCs ideally suited for autologous perinatal regenerative medicine applications.
Get full access to this article
View all access options for this article.
References
1.
JonesGN, MoschidouD, Puga-IglesiasTI, KuleszewiczK, VanleeneM, ShefelbineSJ, Bou-GhariosG, FiskNM, DavidAL, De CoppiP and PVGuillot. (2012). Ontological differences in first compared to third trimester human fetal placental chorionic stem cells. PLoS One, 7:e43395
2.
CaiJ, LiW, SuH, QinD, YangJ, ZhuF, XuJ, HeW, GuoX, et al. (2010). Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J Biol Chem, 285:11227–11234.
3.
FujiokaT, ShimizuN, YoshinoK, MiyoshiH and NakamuraY. (2010). Establishment of induced pluripotent stem cells from human neonatal tissues. Hum Cell, 23:113–118.
4.
LuHE, YangYC, ChenSM, SuHL, HuangPC, TsaiMS, WangTH, TsengCP and HwangSM. (2013). Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells. Exp Cell Res, 319:498–505.
5.
MikiT, LehmannT, CaiH, StolzDB and StromSC. (2005). Stem cell characteristics of amniotic epithelial cells. Stem Cells, 23:1549–1559.
6.
KunisakiSM, ArmantM, KaoGS, StevensonK, KimH and FauzaDO. (2007). Tissue engineering from human mesenchymal amniocytes: a prelude to clinical trials. J Pediatr Surg, 42:974–979; discussion 979–980.
7.
Di CagnoA, BaldariC, BattagliaC, BrasiliP, MerniF, PiazzaM, ToselliS, VentrellaAR and GuidettiL. (2008). Leaping ability and body composition in rhythmic gymnasts for talent identification. J Sports Med Phys Fitness, 48:341–346.
8.
Villa-DiazLG, BrownSE, LiuY, RossAM, LahannJ, ParentJM and KrebsbachPH. (2012). Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. Stem Cells, 30:1174–1181.
9.
Villa-DiazLG, NandivadaH, DingJ, Nogueira-de-SouzaNC, KrebsbachPH, O'SheaKS, LahannJ and SmithGD. (2010). Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol, 28:581–583.
10.
MakSK, HuangYA, IranmaneshS, VangipuramM, SundararajanR, NguyenL, LangstonJW and SchuleB. (2012). Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int, 2012:140427
11.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
12.
BentleyJK, PopovaAP, BozykPD, LinnMJ, BaekAE, LeiJ, GoldsmithAM and HershensonMB. (2010). Ovalbumin sensitization and challenge increases the number of lung cells possessing a mesenchymal stromal cell phenotype. Respir Res, 11:127
13.
Itskovitz-EldorJ, SchuldinerM, KarsentiD, EdenA, YanukaO, AmitM, SoreqH and BenvenistyN. (2000). Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med, 6:88–95.
14.
LivakKJ and SchmittgenTD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25:402–408.
15.
MaheraliN and HochedlingerK. (2008). Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell, 3:595–605.
16.
LiC, ZhouJ, ShiG, MaY, YangY, GuJ, YuH, JinS, WeiZ, ChenF and JinY. (2009). Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum Mol Genet, 18:4340–4349.
17.
LuHE, TsaiMS, YangYC, YuanCC, WangTH, LinXZ, TsengCP and HwangSM. (2011). Selection of alkaline phosphatase-positive induced pluripotent stem cells from human amniotic fluid-derived cells by feeder-free system. Exp Cell Res, 317:1895–1903.
18.
FanY, LuoY, ChenX, LiQ and SunX. (2012). Generation of human beta-thalassemia induced pluripotent stem cells from amniotic fluid cells using a single excisable lentiviral stem cell cassette. J Reprod Dev, 58:404–409.
19.
MoschidouD, MukherjeeS, BlundellMP, DrewsK, JonesGN, AbdulrazzakH, NowakowskaB, PhoolchundA, LayK, et al. (2012). Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Ther, 20:1953–1967.
20.
MoschidouD, MukherjeeS, BlundellMP, JonesGN, AtalaAJ, ThrasherAJ, FiskNM, De CoppiP and GuillotPV. (2013). Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic Acid acquire pluripotent characteristics. Stem Cells Dev, 22:444–458.
21.
MachtayM, PaulusR, MoughanJ, KomakiR, BradleyJ, ChoyH, AlbainK, MovsasB, SauseWT and CurranWJ. (2012). Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma: a radiation therapy oncology group analysis. J Thorac Oncol, 7:716–722.
22.
FauzaD. (2004). Amniotic fluid and placental stem cells. Best Pract Res Clin Obstet Gynaecol, 18:877–891.
23.
SimpsonLL. (2013). Twin-twin transfusion syndrome. Am J Obstet Gynecol, 208:3–18.
24.
HuiL, SlonimDK, WickHC, JohnsonKL and BianchiDW. (2012). The amniotic fluid transcriptome: a source of novel information about human fetal development. Obstet Gynecol, 119:111–118.
25.
PoloJM, LiuS, FigueroaME, KulalertW, EminliS, TanKY, ApostolouE, StadtfeldM, LiY, et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol, 28:848–855.
26.
EvangelistaM, SonciniM and ParoliniO. (2008). Placenta-derived stem cells: new hope for cell therapy?. Cytotechnology, 58:33–42.
27.
LeeJM, JungJ, LeeHJ, JeongSJ, ChoKJ, HwangSG and KimGJ. (2012). Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. Int Immunopharmacol, 13:219–224.
28.
BailoM, SonciniM, VertuaE, SignoroniPB, SanzoneS, LombardiG, ArientiD, CalamaniF, ZattiD, et al. (2004). Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation, 78:1439–1448.
29.
WegmeyerH, BroskeAM, LeddinM, KuentzerK, NisslbeckAK, HupfeldJ, WiechmannK, KuhlenJ, von SchwerinC, et al. (2013). Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev, 22:2606–2618.
30.
GuillotPV, GotherstromC, ChanJ, KurataH and FiskNM. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells, 25:646–654.
31.
AnchanRM, QuaasP, Gerami-NainiB, BartakeH, GriffinA, ZhouY, DayD, EatonJL, GeorgeLL, et al. (2011). Amniocytes can serve a dual function as a source of iPS cells and feeder layers. Hum Mol Genet, 20:962–974.
32.
KooBK, ParkIY, KimJ, KimJH, KwonA, KimM, KimY, ShinJC and KimJH. (2012). Isolation and characterization of chorionic mesenchymal stromal cells from human full term placenta. J Korean Med Sci, 27:857–863.
33.
FarihaMM, ChuaKH, TanGC, TanAE and HayatiAR. (2011). Human chorion-derived stem cells: changes in stem cell properties during serial passage. Cytotherapy, 13:582–593.
34.
MaguireCT, DemarestBL, HillJT, PalmerJD, BrothmanAR, YostHJ and CondicML. (2013). Genome-wide analysis reveals the unique stem cell identity of human amniocytes. PLoS One, 8:e53372
35.
GinsbergM, JamesD, DingBS, NolanD, GengF, ButlerJM, SchachterleW, PulijaalVR, MathewS, et al. (2012). Efficient direct reprogramming of mature amniotic cells into endothelial cells by ETS factors and TGFbeta suppression. Cell, 151:559–575.
36.
LiuT, ZouG, GaoY, ZhaoX, WangH, HuangQ, JiangL, GuoL and ChengW. (2012). High efficiency of reprogramming CD34(+) cells derived from human amniotic fluid into induced pluripotent stem cells with Oct4. Stem Cells Dev, 21:2322–2332.
37.
MaciasMI, GrandeJ, MorenoA, DominguezI, BornsteinR and FloresAI. (2010). Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. Am J Obstet Gynecol, 203:495e9–495 e23.
38.
ToselliM, CerbaiE, RossiF and CattaneoE. (2008). Do amniotic fluid-derived stem cells differentiate into neurons in vitro?. Nat Biotechnol, 26:269–270; Author Reply 270–261.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
